过氧化物酶体增殖物激活受体δ在血管重构中的作用机制研究进展*

doi:10.3870/j.issn.1672-0741.25.10.012

摘要/Abstract

摘要： 血管重构是诸多心血管疾病的核心病理环节,过氧化物酶体增殖物激活受体δ（PPARδ）作为核受体家族的重要成员,不仅在调控能量代谢、炎症反应、氧化应激等生理过程中发挥重要作用,还通过调控血管平滑肌细胞增殖迁移、细胞外基质重塑等多种复杂病理生理过程来影响血管重构进程。深入研究PPARδ在血管重构中的具体作用机制,有助于揭示心血管疾病的发病机制,发现新的干预靶点,从而降低心血管事件风险,改善患者预后。该文对PPARδ的结构、功能以及近年来其在血管重构过程中的作用及机制相关研究进行综述,以期为心血管疾病提供新的治疗靶点。

关键词: 过氧化物酶体增殖物激活受体δ, 血管重构, 氧化应激, 血管平滑肌细胞, 巨噬细胞

Abstract: Vascular remodeling is a pivotal pathological process in numerous cardiovascular diseases. Peroxisome proliferator-activated receptor delta （PPARδ）, a key member of the nuclear receptor family, not only plays a crucial role in regulating physiological processes such as energy metabolism, inflammatory responses, and oxidative stress, but also influences the vascular remodeling process by modulating various complex pathophysiological mechanisms, including the proliferation and migration of vascular smooth muscle cells and extracellular matrix remodeling. In-depth exploration of the specific mechanisms by which PPARδ affects vascular remodeling can help elucidate the pathogenesis of cardiovascular diseases, identifying novel intervention targets, mitigating the risk of cardiovascular events, and improving patient prognosis. This article reviews the structure and function of PPARδ and its recent research on the impact and mechanisms in vascular remodeling, aiming to offer new therapeutic targets for cardiovascular diseases.

Key words: PPARδ, vascular remodeling, oxidative stress, vascular smooth muscle cells, macrophages

中图分类号:

R363.2

唐溪涓, 贺立群. 过氧化物酶体增殖物激活受体δ在血管重构中的作用机制研究进展^*[J]. 华中科技大学学报（医学版）, 2026, 55(5): 752-758.

Tang Xijuan, He Liqun. Mechanisms of Peroxisome Proliferator-Activated Receptor δ in Vascular Remodeling[J]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, 2026, 55(5): 752-758.

参考文献

[1] Totoń-Żurańska J,Mikolajczyk T P,Saju B,et al.Vascular remodelling in cardiovascular diseases:Hypertension,oxidation,and inflammation[J].Clin Sci,2024,138(13):817-850.
[2] Koga T,Peters J M.Targeting peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) for the treatment or prevention of alcoholic liver disease[J].Biol Pharm Bull,2021,44(11):1598-1606.
[3] Rostami A,Palomer X,Pizarro-Delgado J,et al.PPARβ/δ prevents inflammation and fibrosis during diabetic cardiomyopathy[J].Pharmacol Res,2024,210:107515.
[4] Sawada M,Yamamoto H,Ogasahara A,et al.β-aminoisobutyric acid protects against vascular inflammation through PGC-1β-induced antioxidative properties[J].Biochem Biophys Res Commun,2019,516(3):963-968.
[5] Chen S J,Chien H C,Tsai S H,et al.Melatonin ameliorates atherosclerotic plaque vulnerability by regulating PPARδ-associated smooth muscle cell phenotypic switching[J].J Pineal Res,2024,76(5):e12988.
[6] Chen C G,Yi C F,Chen C F,et al.Inhibitory effect of PPARδ agonist GW501516 on proliferation of hypoxia-induced pulmonary arterial smooth muscle cells by regulating the mTOR pathway[J].Curr Med Sci,2023,43(5):979-987.
[7] Xiao L,Wang N.PPAR-δ:A key nuclear receptor in vascular function and remodeling[J].J Mol Cell Cardiol,2022,169:1-9.
[8] Wang G,Yan Y,Sun Q,et al.Distinct roles of PPARs in atherosclerosis[J].ATVB,2026,46(1):68-84.
[9] Usuda D,Kanda T.Peroxisome proliferator-activated receptors for hypertension[J].World J Cardiol,2014,6(8):744-754.
[10] Elmarasi M,Elmakaty I,Elsayed B,et al.Phenotypic switching of vascular smooth muscle cells in atherosclerosis,hypertension,and aortic dissection[J].J Cell Physiol,2024,239(4):e31200.
[11] Kloc M,Uosef A,Kubiak J Z,et al.Role of macrophages and RhoA pathway in atherosclerosis[J].IJMS,2021,22(1):216.
[12] Młynarska E,Kowalik A,Krajewska A,et al.Inflammaging and senescence-driven extracellular matrix remodeling in age-associated cardiovascular disease[J].Biomolecules,2025,15(10):1452.
[13] Cabrera-Fuentes H A,Barreto G,Perez-Campos E,et al.Targeting inflammation and fibrosis in cardiovascular disease:Emerging mechanisms and therapies[J].FASEB J,2025,39(17):e71008.
[14] Lopacinska N,Wesoly J,Bluyssen H A R.Interplay between KLF4,STAT,IRF,and NF-κB in VSMC and macrophage plasticity during vascular inflammation and atherosclerosis[J].Int J Mol Sci,2025,26(20):10205.
[15] Zhao L,Zhang M,Liu Y W,et al.Sinomenine alleviates lipopolysaccharide-induced acute lung injury via a PPARβ/δ-dependent mechanism[J].Eur J Pharmacol,2023,953:175838.
[16] Su M,Zhao W,Jiang H,et al.Endothelial IGFBP6 suppresses vascular inflammation and atherosclerosis[J].Nat Cardiovasc Res,2025,4(2):145-162.
[17] Guo Q,Jin Y,Chen X,et al.NF-κB in biology and targeted therapy:New insights and translational implications[J].Sig Transduct Target Ther,2024,9(1):53.
[18] Ghara A,Matada G S P,Sah R K,et al.Unravelling immunity:Understanding inflammatory pathways as key players in immune response and disease progression[J].Curr Mol Biol Rep,2025,11(1):5.
[19] Zhang J,Tu Y,Wei J,et al.Dectin1 contributes to hypertensive vascular injury by promoting macrophage infiltration through activating the Syk/NF-κB pathway[J].Biochim Biophys Acta Mol Basis Dis,2024,1870(1):166911.
[20] Titus C,Hoque M T,Bendayan R.PPAR agonists for the treatment of neuroinflammatory diseases[J].Trends Pharmacol Sci,2024,45(1):9-23.
[21] Sibille B,Mothe-Satney I,Le Menn G,et al.Gene doping with peroxisome-proliferator-activated receptor beta/delta agonists alters immunity but exercise training mitigates the detection of effects in blood samples[J].Int J Mol Sci,2021,22(21):11497.
[22] Zhang M,Barroso E,Peña L,et al.PPARβ/δ attenuates hepatic fibrosis by reducing SMAD3 phosphorylation and p300 levels via AMPK in hepatic stellate cells[J].Biomed Pharmacother,2024,179:117303.
[23] Gaete P V,Nieves-Barreto L D,Guatibonza-García V,et al.Medium-chain fatty acids modify macrophage expression of metabolic and inflammatory genes in a PPARβ/δ-dependent manner[J].Sci Rep,2023,13(1):11573.
[24] Xu H,Gao K,Liu C,et al.Pathological mechanism of heart failure with preserved ejection fraction in rats based on iTRAQ technology[J].PeerJ,2023,11:e15280.
[25] Myszko M,Bychowski J,Skrzydlewska E,et al.The dual role of oxidative stress in atherosclerosis and coronary artery disease:Pathological mechanisms and diagnostic potential[J].Antioxidants (Basel),2025,14(3):275.
[26] Ardahanlı İ,Aslan R,Arıkan E,et al.Redox imbalance and oxidative stress in cardiovascular diseases:Mechanisms,biomarkers,and therapeutic targets[J].Arch Med Sci Atheroscler Dis,2025,10(1):220-227.
[27] Miao L,Zhou Y,Tan D,et al.Ginsenoside Rk1 improves endothelial function in diabetes through activating peroxisome proliferator-activated receptors[J].Food Funct,2024,15(10):5485-5495.
[28] Papatheodorou I,Galatou E,Panagiotidis G D,et al.Cardioprotective effects of PPARβ/δ activation against ischemia/reperfusion injury in rat heart are associated with ALDH2 upregulation,amelioration of oxidative stress and preservation of mitochondrial energy production[J].Int J Mol Sci,2021,22(12):6399.
[29] Papatheodorou I,Makrecka-Kuka M,Kuka J,et al.Pharmacological activation of PPARβ/δ preserves mitochondrial respiratory function in ischemia/reperfusion via stimulation of fatty acid oxidation-linked respiration and PGC-1α/NRF-1 signaling[J].Front Endocrinol,2022,13:941822.
[30] 李咏,刘立,徐隽,等.PPARδ激动剂GW501516通过调节线粒体生物合成对大鼠I/R后神经损伤的保护作用[J].西部医学,2023,35(10):1459-1464.
Li Y,Liu L,Xu J,et al.Protective effect of PPARδ agonist GW501516 on neural injury after ischemia/reperfusion in rats by regulating mitochondrial biosynthesis[J].Medical Journal of West China,2023,35(10):1459-1464.
[31] Usatyuk P V,Natarajan V.Hydroxyalkenals and oxidized phospholipids modulation of endothelial cytoskeleton,focal adhesion and adherens junction proteins in regulating endothelial barrier function[J].Microvasc Res,2012,83(1):45-55.
[32] 陈昌贵,易春峰,余志华,等.GW501516对低氧致肺动脉内皮细胞损伤的影响及机制[J].中国药房,2024,35(2):179-185.
Chen C G,Yi C F,Yu Z H,et al.Effects of GW501516 on the injury of pulmonary artery endothelial cells induced by hypoxia and its mechanism[J].China Pharmacy,2024,35(2):179-185.
[33] Liu Y X,Guo F M,Qiu W J,et al.Metabolic reprogramming and cell interaction in atherosclerosis:From molecular mechanisms to therapeutic strategies[J].J Cardiovasc Dev Dis,2025,12(10):384.
[34] Cai J,Zhang M,Liu Y,et al.Iron accumulation in macrophages promotes the formation of foam cells and development of atherosclerosis[J].Cell Biosci,2020,10(1):137.
[35] Yanai H,Adachi H,Hakoshima M,et al.Metabolic-dys-function-associated steatotic liver disease—Its pathophysiology,association with atherosclerosis and cardiovascular disease,and treatments[J].Int J Mol Sci,2023,24(20):15473.
[36] Qiu Y Y,Zhang J,Zeng F Y,et al.Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)[J].Pharmacol Res,2023,192:106786.
[37] Zarei M,Aguilar-Recarte D,Palomer X,et al.Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease[J].Metabolism,2021,114:154342.
[38] Shin K C,Huh J Y,Ji Y,et al.VLDL-VLDLR axis facilitates brown fat thermogenesis through replenishment of lipid fuels and PPARβ/δ activation[J].Cell Rep,2022,41(11):111806.
[39] Guisantes-Batan E,Mazuecos L,Rubio B,et al.Grape seed extract supplementation modulates hepatic lipid metabolism in rats.Implication of PPARβ/δ[J].Food Funct,2022,13(21):11353-11368.
[40] Wang M,Zhu Z,He X,et al.The crosstalk between mitochondrial dysfunction and fatty acid metabolism in heart failure:Mechanisms and therapeutic strategies[J].Front Pharmacol,2025,16:1679085.
[41] Zhou C,Zhang W,Lin H,et al.Effect of theaflavin-3,3'-digallate on leptin-deficient induced nonalcoholic fatty liver disease might be related to lipid metabolism regulated by the Fads1/PPARδ/Fabp4 axis and gut microbiota[J].Front Pharmacol,2022,13:925264.
[42] Zhang H,Jiang L,Guo Z,et al.PPARβ/δ,a novel regulator for vascular smooth muscle cells phenotypic modulation and vascular remodeling after subarachnoid hemorrhage in rats[J].Sci Rep,2017,7:45234.
[43] 陈昌贵,易春峰,王栋,等.PPARδ的激活通过抑制糖酵解减轻PDGF-BB诱导的肺动脉平滑肌细胞表型转化[J].中国病理生理杂志,2023,39(6):988-995.
Chen C G,Yi C F,Wang D,et al.Activation of PPARδ suppresses phenotypic switching of PDGF-BB-induced pulmonary artery smooth muscle cells via inhibition of glycolysis[J].Chinese Journal of Pathophysiology,2023,39(6):988-995.
[44] Ke R,Liu L,Zhu Y,et al.Knockdown of AMPKα2 promotes pulmonary arterial smooth muscle cells proliferation via mTOR/Skp2/p27Kip1 signaling pathway[J].Int J Mol Sci,2016,17(6):844.
[45] Wang J,Wu Q,Wang X,et al.Targeting macrophage phenotypes and metabolism as novel therapeutic approaches in atherosclerosis and related cardiovascular diseases[J].Curr Atheroscler Rep,2024,26(10):573-588.
[46] 耿田欣. CD137信号通过STAT6/PPARδ通路调控动脉粥样硬化中巨噬细胞M2极性转变[D].镇江:江苏大学,2020.
Geng T X.CD137 signaling induces macrophage M2 polarization in atherosclerosis through STAT6/PPARδ pathway[D].Zhenjiang:Jiangsu University,2020.
[47] Doran A C,Yurdagul A,Tabas I.Efferocytosis in health and disease[J].Nat Rev Immunol,2020,20(4):254-267.
[48] Korns D,Frasch S C,Fernandez-Boyanapalli R,et al.Modulation of macrophage efferocytosis in inflammation[J].Front Immunol,2011,2:57.
[49] Bojic L A,Huff M W.Peroxisome proliferator-activated receptor δ:A multifaceted metabolic player[J].Curr Opin Lipidol,2013,24(2):171-177.
[50] Mukundan L,Odegaard J I,Morel C R,et al.PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance[J].Nat Med,2009,15(11):1266-1272.
[51] Heo K S,Cushman H J,Akaike M,et al.ERK5 activation in macrophages promotes efferocytosis and inhibits atherosclerosis[J].Circulation,2014,130(2):180-191.

过氧化物酶体增殖物激活受体δ在血管重构中的作用机制研究进展^*

Mechanisms of Peroxisome Proliferator-Activated Receptor δ in Vascular Remodeling

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马静, 乔彦霞, 刘伟娜, 白星宇, 张明. 维生素A、E通过抑制COX-2表达改善坏死性小肠结肠炎新生大鼠肠道损伤^*[J]. 华中科技大学学报（医学版）, 2026, 55(3): 346-353.
[2]	李沐哲, 李伟龙, 刘鑫, 王林华, 杨少锋. 巨噬细胞衰老在骨质疏松症发生发展中的作用研究进展^*[J]. 华中科技大学学报（医学版）, 2026, 55(3): 438-442.
[3]	张琼, 张涛, 李娜, 吴志林. 瑞马唑仑调控Nrf2/HO-1信号通路对哮喘小鼠气道炎症的影响^*[J]. 华中科技大学学报（医学版）, 2026, 55(1): 20-26.
[4]	傅青雯, 尤浩军, 雷静. Nrf2通路在常见周围神经病中抗氧化应激的作用机制^*[J]. 华中科技大学学报（医学版）, 2026, 55(1): 140-145.
[5]	王卓, 胡乃范, 江琦, 钟荣, 田剑波, 缪小平△ , 朱颖△. 氧化应激在环境双酚类物质暴露与肝功能关系中的中介效应[J]. 华中科技大学学报（医学版）, 2025, 54(6): 874-883.
[6]	马丽娜, 王伟, 汪丽云△. 炎症和脂代谢紊乱在肝纤维化中的作用机制[J]. 华中科技大学学报（医学版）, 2025, 54(6): 908-915.
[7]	赵琦, 陈萍, 杨丽萍, 孙建华. IGF-1与氧化应激在多囊卵巢综合征中的作用机制[J]. 华中科技大学学报（医学版）, 2025, 54(5): 750-755.
[8]	谭凤娇, 霍博, 蒋丁胜, 方泽民. HDAC3-Akt通路在血管平滑肌细胞增殖中的作用[J]. 华中科技大学学报（医学版）, 2025, 54(4): 465-469.
[9]	武小杰, 杨硕, 查干, 王爱利. Danthron通过靶向GRIM-12影响Nrf2/HO-1通路缓解COPD中的氧化应激和炎症反应[J]. 华中科技大学学报（医学版）, 2025, 54(1): 1-7.
[10]	高然, 刘晨雨, 邓超华, 胡维琨. 自身免疫性疾病中NETs与免疫细胞的相互作用[J]. 华中科技大学学报（医学版）, 2025, 54(1): 129-136.
[11]	陈娅莉, 何啸兰, 谈秀娟, 刘莉, 周月希. 丹酚酸B通过RORA/SENP1调控复发性流产中的滋养层细胞-巨噬细胞相互作用[J]. 华中科技大学学报（医学版）, 2024, 53(6): 733-740.
[12]	刘禹杉, 张仪霖, 杨树森, 惠毅, 闫曙光, 周永学. NAD+调节细胞衰老机制与特发性肺纤维化疾病的研究进展[J]. 华中科技大学学报（医学版）, 2024, 53(6): 852-857.
[13]	蔡君艳, 朱迪迪. miR-29b通过KLF4调控血管平滑肌细胞增殖及表型蛋白表达[J]. 华中科技大学学报（医学版）, 2024, 53(5): 615-620.
[14]	叶剑楠, 魏翔, 冯鑫. 人主动脉血管平滑肌细胞铁死亡模型的建立[J]. 华中科技大学学报（医学版）, 2024, 53(4): 427-432.
[15]	王强, 冯靖, 谭章勇, 杨晓江. 吴茱萸碱调节NF-κB通路对膝骨关节炎巨噬细胞极化的影响[J]. 华中科技大学学报（医学版）, 2024, 53(4): 444-451.